New device aims to help women with bladder leakage
NCT ID NCT05828979
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new artificial urinary sphincter device in 6 women with stress incontinence (leaking urine during activity). The goal is to see if the device is safe and works well. Researchers will check how many devices need to be removed or fixed, and if pad weight tests show improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 6 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged \>18 years old * Female patient * Cognitively able and willing to sign an informed consent * Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months * Use of medically acceptable contraception, if of childbearing potential * Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints * Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator * Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator * Life expectancy ≥ 5 years as assessed by the investigator * Affiliated with an appropriate social security system * Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, ACT, etc. (excluding other AUS devices) * Negative urine culture prior to the procedure * Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests * Clinically insignificant post-void residual (PVR) urine defined as \< 50 ml and/or no greater than 10% of the voided volume * Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary Exclusion Criteria: * Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months * Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing her from giving her consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn her consent) * Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions * Pregnant patient, or patient planning pregnancy during the study duration * Patient presenting one or several contraindications of the device * Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes * Known allergy to UroMems eAUS implantable components * History of pelvic irradiation (external beam therapy or brachytherapy) * Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of \>12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of \>9% (75 mmol/mol) over the preceding 3 months * History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value \>70 * Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured * Previous AUS implant * Currently has another Active Implantable Medical Device (AIMD) implanted * Urge incontinence, mixed incontinence (MI) with a predominant urgency component * Overflow urinary incontinence * Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods * Abnormal or poor bladder compliance defined as being \<30 ml/ cm H2O * Bladder neck or urethral stricture that may require any long-term instrumental treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stress urinary incontinence in women are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nantes
Nantes, France
-
Groupe Hospitalier Pitié-Salpêtrière
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Magnetic chair therapy aims to strengthen pelvic floor without surgery
- Beyond the pelvis: could hip and leg alignment hold clues to stress incontinence?
- Could a simple video calm nerves before a bladder test?
- Ultrasound aims to capture pelvic floor movement under the barbell
- Do High-Impact sports raise the risk of leakage? study investigates
- New adjustable implant aims to stop leakage in women